ÂÜÀòÂÒÂ×

Ruby Holder currently serves as Chief Strategy Officer at Proteovant Therapeutics since May 2021, following a role as Vice President of Governance at Roivant Sciences from 2020 to May 2021. Prior to that, Ruby held the position of Vice President of Business Development at Roivant Sciences from 2016 to 2019. Ruby's career also includes experience as a Portfolio Manager and Healthcare Investor at Straus Asset Management and Greywall Asset Management from 2002 to 2015. Ruby Holder holds a Bachelor of Science in Biomedical/Medical Engineering and an MBA from Duke University and The Fuqua School of Business, respectively.